Company Analysis
Sign in

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE: LCTX · Biological Products, (No Diagnostic Substances) · Carlsbad, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.6
◀ Past 6.1● Present 5.5▶ Future 5.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

68 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lineage Cell Therapeutics, Inc.’s names, not what it holds today.

Patents granted
68
68 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 2 in 2024 and none in 2023
Applications published
80
5 of them in 2025
Names they are printed under
7
a former name, a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Pharmaceuticals4
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
BioTime, Inc. a former name
US, as the owner printed on each patent
35 granted
6 published
ES CELL INTERNATIONAL PTE LTD a subsidiary
SG, as the owner printed on each patent. 6 more under the same name are not counted (printed in US, printed in AU)
22 granted
17 published
CELL CURE NEUROSCIENCES LTD. a subsidiary
named as the applicant on its applications, in IL
0 granted
20 published
BioTime, Inc. a former name
named as the applicant on its applications, in US
0 granted
16 published
CELL CURE NEUROSCIENCES LTD. a subsidiary
IL, as the owner printed on each patent
8 granted
7 published
Lineage Cell Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
11 published
LINEAGE CELL THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
3 granted
3 published
Names not counted (1)
ES Cell International Pte. Ltd
Most of its patents print US; this name counts in SG. 0 granted and 9 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 22, 202512,365,872Methods for differentiating pluripotent stem cells in dynamic suspension cultureBiotechnologyLINEAGE CELL THERAPEUTICS, INC.
Jan 21, 202512,203,097Preparation of retinal pigment epithelium cellsPharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Jan 7, 202512,188,047Preparation of retinal pigment epithelium cellsBiotechnologyCELL CURE NEUROSCIENCES LTD.
May 21, 202411,987,810RPE cell populations and methods of generating samePharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Feb 6, 202411,891,622RPE cell populations and methods of generating samePharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Dec 14, 202111,198,849Method for stem cell culture and cells derived therefromBiotechnologyES CELL INTERNATIONAL PTE LTD
Aug 17, 202111,090,337Preparation of photoreceptors for the treatment of retinal diseasesBiotechnologyCELL CURE NEUROSCIENCES LTD.
Jul 20, 202111,066,642Preparation of retinal pigment epithelium cellsPharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Jun 15, 202111,035,857Methods of selecting retinal pigmented epithelial cellsAnalysis of biological materialsCELL CURE NEUROSCIENCES LTD.
Feb 16, 202110,920,191Methods of screening embryonic progenitor cell linesBiotechnologyLINEAGE CELL THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0327026PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLSPharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Aug 21, 20252025/0262248METHODS AND COMPOSITIONS FOR TREATING VISION LOSSBiotechnologyCELL CURE NEUROSCIENCES LTD.
Jul 3, 20252025/0215395PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLSBiotechnologyCELL CURE NEUROSCIENCES LTD.
Jul 3, 20252025/0215394PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLSBiotechnologyCELL CURE NEUROSCIENCES LTD.
Feb 20, 20252025/0057886METHODS AND COMPOSITIONS FOR TREATING HEARING LOSSPharmaceuticalsLineage Cell Therapeutics, Inc.
Sep 12, 20242024/0301351RPE CELL POPULATIONS AND METHODS OF GENERATING SAMEPharmaceuticalsCELL CURE NEUROSCIENCES LTD.
Sep 12, 20242024/0299625METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONSMedical technologyLineage Cell Therapeutics, Inc.
Aug 29, 20242024/0285693EXPANSION OF RETINAL PIGMENT EPITHELIUM CELLSPharmaceuticalsCELL CURE NEUROSCIENCES LTD.
May 16, 20242024/0158745METHODS OF GENERATING OLIGODENDROCYTE PROGENITOR CELLS AND USE THEREOFPharmaceuticalsLineage Cell Therapeutics, Inc.
Oct 5, 20232023/0313127COMPOSITIONS AND METHODS FOR EMBRYONIC STEM CELL EXPANSIONBiotechnologyLineage Cell Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 3 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LCTX · research, not advice